Measuring Drug Target Success

Summary

The episode explores how drug targets are identified and validated, highlighting genetic, animal, and in‑vitro evidence as key sources. It discusses the limited predictive power of pre‑clinical data, noting that genetically validated targets double the odds of clinical success while repeating failed mechanisms increases failure risk. The host emphasizes that despite the necessity of human trials, better early‑stage target selection—especially leveraging genetic validation—can improve ROI in drug development.